Go to journal home page - Vaccine

Vaccine

Submit your articleGuide for authors

About the journal

The official journal of The Japanese Society for Vaccinology.



Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public …

Vaccine: X
$3650

Article publishing charge
for open access

132 days
Review time
139 days
Submission to acceptance
11 days
Acceptance to publication
View all insights

Editor-in-Chief

View full editorial board

Gregory A. Poland, MD

Mayo Foundation for Medical Education and Research, Rochester, United States of America

Articles

DiscussionNo access

Minimal interval for the administration of a pneumococcal polysaccharide vaccine following the administration of a pneumococcal conjugate vaccine

Philippe De Wals, Michaël Desjardins
30 April 2024
Short communicationOpen access

The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure

Jan Biegus, ... Piotr Ponikowski
30 April 2024View PDF
Short communicationAbstract only

Effectiveness of COVID-19 vaccination against school absenteeism in children and adolescents hospitalized with COVID-19

Helena C. Maltezou, ... Emmanuel Roilides
30 April 2024
Short communicationAbstract only

Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial

Holly E. Baum, ... Rajeka Lazarus
30 April 2024
Short communicationAbstract only

Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12–17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination

Chia-Yin Chong, ... Chee-Fu Yung
30 April 2024
Research articleOpen access

Is vaccination against measles, mumps, and rubella associated with reduced rates of antibiotic treatments among children below the age of 2 years? Nationwide register-based study from Denmark, Finland, Norway, and Sweden

Lise Gehrt, ... Signe Sørup
30 April 2024View PDF
Research articleOpen access

Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021–23

Pasquale Stefanizzi, ... Silvio Tafuri
30 April 2024View PDF
Research articleOpen access

Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation

G. Tembo, ... K.C. Jambo
30 April 2024View PDF
Read latest issue

More from Vaccine

View all news

Calls for papers

Precision Vaccines: Biomarkers of vaccine safety and efficacy in vulnerable populations

Guest editors: Dr. Nicola Cotugno, Dr. Asimenia Angelidou, Dr. Donato Amodio, Dr. Amy Sherman, Dr. Paolo Palma and Dr. Ofer Levy
Vaccines prevent ~3 million deaths every year and are a core strategy in the fight against antimicrobial resistance worldwide. Vulnerable populations (VPs), including pregnant women, term and preterm newborns and young infants, older adults and …
Submission deadline: 15 June 2024
View all calls for papers for special issues

Special issues and article collections

Latest developments in vaccine research: The 16th Vaccine Congress

Edited by Dior Beerens Elsevier, Amsterdam, The Netherlands, Gregory Poland Mayo Clinic and Foundation, Rochester, MN, USA
26 January 2024

ML-Driven Vaccine against COVID-19: Developmental Challenges and Foresight

Edited by Simone Pecetta, Fabio Bagnoli, Rino Rappuoli
19 January 2024

Vaccine Value Profiles for Pathogens of Public Health Importance, Volume 1

Edited by Mark Jit
3 November 2023

Canadian COVID-19 Experiences

Edited by Helena Maltezou National Public Health Organization, Athens, Greece
31 May 2023
View all special issues and article collections
View all issues

Partner journals

Vaccine: X

Vaccine: X

Open access

Vaccine: X is the open access companion journal of Vaccine and has the same aims and scope. The journal offers authors who want to publish in a gold open access journal the opportunity to make their work immediately and permanently accessible.

Vaccine: X publishes high quality science across all …

View full aims & scope
Print ISSN: 0264-410X
Online ISSN: 1873-2518

Copyright © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

For authors
Resources for authorsTrack your accepted paperJournal FinderResearcher AcademyRights and permissionsJournal Article Publishing Support Center
For editors
Resources for editorsPublishing Ethics Resource KitGuest editors
For reviewers
Resources for reviewersReviewer recognition